The US Food and Drug Administration (FDA) has approved the use of the orally active drug (Uptravi or selexipag) for the treatment of pulmonary arterial hypertension (PAH).
Its Swiss producing company Actelion Ltd has made the announcement on its website.
Selexipag offers treatment to delay disease progression and reduce risk of hospitalization for PAH which will be made available to patients in the US in early January 2016, the company says.
The company has also announced for an investor conference call and webcast to discuss the approval.
Photo: ACTELION
